Lake Street analyst Thomas Flaten maintained a Buy rating on Evaxion Biotech (EVAX – Research Report) today and set a price target of $6.00.
Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders’ equity requirement Evaxion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback